EP1589946A2 - Solution for nostril wash - Google Patents
Solution for nostril washInfo
- Publication number
- EP1589946A2 EP1589946A2 EP03815343A EP03815343A EP1589946A2 EP 1589946 A2 EP1589946 A2 EP 1589946A2 EP 03815343 A EP03815343 A EP 03815343A EP 03815343 A EP03815343 A EP 03815343A EP 1589946 A2 EP1589946 A2 EP 1589946A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- nostril
- solution
- wash
- diseases
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 7
- 239000008103 glucose Substances 0.000 claims abstract description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 5
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 5
- 239000001103 potassium chloride Substances 0.000 claims abstract description 5
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 5
- 239000011734 sodium Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 230000001143 conditioned effect Effects 0.000 claims description 3
- 150000003841 chloride salts Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 3
- 210000003097 mucus Anatomy 0.000 abstract description 3
- 238000001356 surgical procedure Methods 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 206010039509 Scab Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 2
- 239000012153 distilled water Substances 0.000 abstract description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 4
- 230000002411 adverse Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 241000700198 Cavia Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
Definitions
- the presented solution consists of a therapy supporting of the diseases nostril (rinites, sinusites, allergies, etc.) and powders-operative of nostril surgeries.
- the nostril wash seeks to improve the patient's breathing, benefiting in the treatment of the nostril diseases.
- the present object is destined to allow the hygiene of the nostril and coadjutant cavities, in the treatment of pathologies as rinorreia (mucous membrane and festering); rinites (infectious and obstructive vasomotor), sinusites and rinossinusites and powders- operative of nostril surgeries (aesthetics and reparative).
- the allergic rinite is the most frequent of the diseases, could be seasonal, perennial and mixed (allergic and bacterial), being characterized by sneezes, limpid rinorreia or mucopurulenta. itch and nostril congestion, that can be accompanied of ocular and other symptoms.
- the inflammatory process doesn't just affect the nostril cavity, but also copper the breasts nostril so that the morbidade not only it depends on the disease, but also of your complications: sinusite, dysfunction of Eustaquio's trumpet, alterations of the sleep (nostril congestion).
- sinusite dysfunction of Eustaquio's trumpet
- alterations of the sleep nostril congestion.
- they are used the nostril washes frequently with saline solution (NaCl to 0,9%) and plus, now, the saline solutions with sea water, physiologic serum and solutions 1 with conserving.
- saline solution NaCl to 0,9%
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Refers the present invention, to an unpublished solution for the nostril wash, kindred of removing secretions, crusts and mucus, unblock the nostril cavity. The presented solution, it consists of a therapy supporting of the diseases nostril (rinites, sinusites, allergies, etc.) and powders-operative of nostril surgeries, through a solution composed of chloride of sodium, potassium chloride, glucose and distilled water, the nostril wash seeks to improve the patient’s breathing, benefiting in the treatment of the nostril diseases.
Description
Title: "SOLUTION FOR NOSTRIL WASH. " DESCRIPTION OF THE PATENT Refers the present invention, to an unpublished solution for the nostril wash, kindred of removing secretions, crusts and mucus, unblock the nostril cavity. The presented solution, it consists of a therapy supporting of the diseases nostril (rinites, sinusites, allergies, etc.) and powders-operative of nostril surgeries. Through a solution composed of chloride of sodium, potassium chloride, glucose and distilled water, the nostril wash seeks to improve the patient's breathing, benefiting in the treatment of the nostril diseases. The present object is destined to allow the hygiene of the nostril and coadjutant cavities, in the treatment of pathologies as rinorreia (mucous membrane and festering); rinites (infectious and obstructive vasomotor), sinusites and rinossinusites and powders- operative of nostril surgeries (aesthetics and reparative). The allergic rinite is the most frequent of the diseases, could be seasonal, perennial and mixed (allergic and bacterial), being characterized by sneezes, limpid rinorreia or mucopurulenta. itch and nostril congestion, that can be accompanied of ocular and other symptoms. The inflammatory process doesn't just affect the nostril cavity, but also copper the breasts nostril so that the morbidade not only it depends on the disease, but also of your complications: sinusite, dysfunction of Eustaquio's trumpet, alterations of the sleep (nostril congestion). In your conventional treatment, they are used the nostril washes frequently with saline solution (NaCl to 0,9%) and plus, now, the saline solutions with sea water, physiologic serum and solutions
1 with conserving. However, such solutions present in your majority,
2 collateral effects to the patients, being able to
3
4 to arrive to the compromising of the eyelashes of the mucous
5 membrane.
6 The solution for now presented, it doesn't possess conserving
7 and the cloret's used in your composition (KCI and NaCl) with the
8 glucose they are component found in the human blood (it shapes) and
9 also in the nostril cavity, in other words, it is a closer solution of the lo physiologic, being also a solution hypertonic, however without causing ii the adverse collateral effects in the nostril mucous membranes, plus,
12 only the longed for benefits, such as: the unblock of the passage of the
13 air for the nostril cavity, benefiting in the treatment of the diseases.
14 The percentile ones used in the solution, they were equation is the starting from studies and tests accomplished in small animals ie (guinea-pigs), aiming at a solution to reach the benefits of the nostril 17 wash, however without causing adverse effects to the patients. It is a is solution more hypertonica than the physiologic serum, however without
19 reaching high tonic indexes, seeking a better clinical use of the
20 patients.
2i In the accomplished study, it was verified that the continuous
22 use of the physiologic serum can cause an effect it bounces of
23 increase in the production in the mucus and that the continuous use of
24 the presented solution, didn't cause the collateral effects presented by
25 the serum. Besides, this solution doesn't present conserve, which more
26 it approximates her/it of the physiologic, however, it should come
27 conditioned tightly in disposable and closed flasks to avoid the infection
28 possibility for bacterial that are proliferated in habitat the glucose base.
i The study was for the percentile of the composition of each
2 component, so that if it reached an appropriate solution for the
3 expected objective. Your composition is made of chloride of sodium (NaCl) to 1,2%, mixed with potassium chloride (KCI) to 0,03%,
5 mixed with glucose to 1% and water distilled to 100ml.
6 In agreement with the description and in your details, the
7 "SOLUTION FOR NOSTRIL WASH," for now in subject, it is s characterized by being constituted of a solution for nostril wash (1), 9 possessing a composition of chloride of sodium (NaCl) to 1,2% (2), o mixed with potassium chloride (KCI) to 0,03% (3), mixed with glucose i to 1% (4) and water distilled to 100ml (5), to be conditioned in flasks 2 closed tightly and you discarded (6). s For the advantages that offers and for covering truly of 4 characteristics innovative, the "SOLUTION FOR NOSTRIL WASH.", it s gathers the necessary conditions to deserve the Privilege of Patent of 6 Invention.
Claims
CLAIMS 1a) "SOLUTION FOR NOSTRIL WASH.", characterized by being constituted of a solution for nostril wash (1), possessing a composition of chloride of sodium (NaCl) to 1,2% (2), mixed with potassium chloride (KCI) to 0,03% (3), mixed with glucose to 1% (4) and water distilled to 100ml (5), to be conditioned in flasks closed tightly and you discarded (6).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR0301165 | 2003-01-23 | ||
| BR0301165-8A BR0301165A (en) | 2003-01-23 | 2003-01-23 | Nasal wash solution |
| PCT/BR2003/000181 WO2004064708A2 (en) | 2003-01-23 | 2003-12-02 | Solution for nostril wash |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1589946A2 true EP1589946A2 (en) | 2005-11-02 |
Family
ID=32739200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03815343A Withdrawn EP1589946A2 (en) | 2003-01-23 | 2003-12-02 | Solution for nostril wash |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1589946A2 (en) |
| BR (1) | BR0301165A (en) |
| WO (1) | WO2004064708A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101770752B1 (en) * | 2016-01-19 | 2017-08-24 | 정호철 | nasal cavity cleaner |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815360A1 (en) * | 1988-05-05 | 1989-11-16 | Dibbert Hans Juergen Dr Med | Use of an aqueous glucose solution as medium for rinsing the nasal and/or pharyngeal space |
| JP2681527B2 (en) * | 1990-02-15 | 1997-11-26 | ジャパンファインケミカル株式会社 | Topical for promoting cell activity |
| FR2780650B1 (en) * | 1998-07-03 | 2000-09-08 | Goemar Lab Sa | SALINE SOLUTIONS, THEIR PREPARATION METHOD AND MEDICINAL PRODUCTS BASED ON SUCH SOLUTIONS |
-
2003
- 2003-01-23 BR BR0301165-8A patent/BR0301165A/en not_active IP Right Cessation
- 2003-12-02 WO PCT/BR2003/000181 patent/WO2004064708A2/en not_active Application Discontinuation
- 2003-12-02 EP EP03815343A patent/EP1589946A2/en not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2004064708A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004064708A2 (en) | 2004-08-05 |
| BR0301165A (en) | 2005-05-10 |
| WO2004064708A3 (en) | 2004-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tilahun | Case REPORT-vaginal leech Infestation: a rare cause of Hypovolumic shock in postmenopausal woman | |
| Steele | Forum on the tonsil and adenoid problem in orthodontics An otolaryngologist views the tonsil and adenoid problem | |
| Bokhari et al. | Growing burden of noncommunicable diseases: the contributory role of oral diseases, Eastern Mediterranean Region perspective. | |
| EP1589946A2 (en) | Solution for nostril wash | |
| CN114480271A (en) | Umbilical cord mesenchymal stem cell exosomes for promoting healing of intractable pressure ulcers and preparation method thereof | |
| RU2667653C1 (en) | Method for treatment of inflammatory diseases of the mucous membranes using a powdered form of platelet autologous plasma | |
| Khosroshahi et al. | Keutel syndrome: a report of four cases | |
| Hilding | Syndrome of joint and cartilaginous pathologic changes with destructive iridocyclitis: Comparison with described concurrent eye and joint diseases | |
| Bartley | Nasal influences on breathing | |
| Sebazungu et al. | Leech infestation in the vulvar region: causes of vaginal bleeding in a six years old child | |
| Kiselev et al. | Cough as a sign of post-nasal drip syndrome | |
| Oliphant et al. | Sulfadiazine in lymphogranuloma venereum ophthalmitis | |
| CN203988967U (en) | Wash nose device | |
| CN216417725U (en) | Traditional chinese and western medicine combines internal medicine massage device | |
| RU2757578C1 (en) | Method for the treatment of adenoiditis in children | |
| Mehrvarz et al. | Acute Myeloblastic leukemia and Marfan syndrome: A Case Report and Literature Review | |
| Yakubovich | EVALUATION OF THE EFFECTIVENESS OF COMPLEX APPLICATION OF OZONE IN CHRONIC SUPPUROUS EAR DISEASES | |
| Gonchar et al. | Rare cardio-respiratory findings in goldenhar syndrome (case report) | |
| Mehrvarz et al. | Case Report Acute Myeloblastic leukemia and Marfan syndrome: A Case Report and | |
| Saha et al. | Ascaris lumbrocoides in the Right Maxillary Sinus-a rare case | |
| Shukurov | CHANGES IN THE PERIODONTAL TISSUES IN PATIENTS WITH CHRONIC LIVER DISEASE | |
| RU2372948C1 (en) | Method of treating chronic obstructive pulmonary disease | |
| Lomaia et al. | Modern aspects of chronic rhinosinusitis treatment | |
| Ogli et al. | THE MECHANISM OF DEVELOPMENT AND IMPROVEMENT OF TREATMENT OF ACUTE SINUSITIS OCCURRING WITH A BLOCK OF NATURAL ANASTOMOSIS | |
| Bickel et al. | Large Bullous Lung Disease in a Child with Proteus Syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20050822 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| RBV | Designated contracting states (corrected) |
Designated state(s): DE ES FR GB IT PT |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20070703 |